Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro-10-9359) Tigason.
In an open trial, eight patients with psoriasis took part in a four-month study to evaluate the effect of a new oral synthetic retinoid Ro-10-9359 (Tigason). All patients improved on the treatment, although one had side effects severe enough to force dosage reduction with less satisfactory control.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D013997:Time Factors; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use*; D014987:Xerostomia / Q000139:chemically induced
D014212:Tretinoin